Select a medication above to begin.
Elinzanetant
elinzanetant
Adult Dosing .
Dosage forms: CAP: 60 mg
Investigational New Drug (IND)
- [pending FDA approval]
vasomotor sx, mod-severe menopausal
- [indication/patient population pending FDA approval]
- Info: antagonizes neurokinin 1 and 3 receptors on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, modulating neuronal activity involved in thermo- and sleep regulation; avail. internationally as Lynkuet
Peds Dosing .
- Dosage forms: --
Investigational New Drug (IND)
- [pending FDA approval]
- Info: not anticipated to be applicable to Peds population